News

Verona Pharma: Upcoming Conferences and Innovations in Health

Verona Pharma: Upcoming Conferences and Innovations in Health

Exciting Opportunities Ahead for Verona Pharma

Verona Pharma plc (NASDAQ: VRNA) recently announced a significant milestone as it prepares for its participation in a series of influential healthcare conferences taking place in March 2025. This initiative showcases the company's commitment to advancing its mission of delivering innovative solutions for chronic respiratory diseases, a sector where there is a substantial demand for effective treatments.

Upcoming Conferences in March 2025

In the upcoming month, Verona Pharma's senior management will present an overview of the company's current and future projects at two important events. The first is the TD Cowen 45th Annual Health Care Conference, scheduled for March 3, 2025. This event offers a platform for Verona Pharma to engage with investors and share insightful developments regarding their product pipeline.

TD Cowen 45th Annual Health Care Conference Details

During the TD Cowen conference, which will occur at 11:10 a.m. ET, Verona Pharma will showcase its latest advancements and position within the biopharmaceutical industry. The presentation will be accessible to investors interested in learning more about the company’s strategic direction and ongoing projects.

Leerink Partners 2025 Global Healthcare Conference

Following the TD Cowen event, Verona Pharma will also participate in the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 8:40 a.m. ET. This conference is another opportunity for the company to strengthen its relationships with stakeholders and articulate its strategies to address chronic respiratory conditions.

Webcast Availability

For those unable to attend in person, Verona Pharma ensures transparency and accessibility by providing a webcast of each conference presentation. Interested parties can easily access these webcasts through the Events and Presentations link found on the Investors section of Verona Pharma's official website.

Verona Pharma's Commitment to Innovation

Verona Pharma is at the forefront of developing therapies that fill the gap in treatment options for chronic respiratory diseases. With a primary focus on significant unmet medical needs, the company has made remarkable progress with its lead product, Ohtuvayre™ (ensifentrine). This groundbreaking inhaled therapy combines both bronchodilator and anti-inflammatory effects to provide comprehensive care for patients suffering from Chronic Obstructive Pulmonary Disease (COPD).

Potential Applications for Ensifentrine

Ensifentrine's unique properties also make it a promising candidate for treating other serious respiratory conditions, including cystic fibrosis and asthma. The ability to address multiple diseases within the respiratory spectrum highlights Verona Pharma's innovative approach and dedication to providing effective solutions where they are needed most.

Contact Information for Inquiries

To facilitate further discussions or inquiries regarding their highlights and product developments, Verona Pharma encourages interested parties to reach out through the following contacts:

Verona Pharma plc

For general inquiries, please contact the company at Tel: +1-844-341-9901.

For Investor Relations

Victoria Stewart, Senior Director of Investor Relations and Communications, can be reached via email at IR@veronapharma.com.

For US Investor Enquiries

Investors can also connect with Argot Partners at Tel: +1-212-600-1902 or email verona@argotpartners.com.

For Media Inquiries

For international and US media inquiries, reach Ten Bridge Communications at Tel: +1-781-316-4424 or email tbcverona@tenbridgecommunications.com.

Frequently Asked Questions

What is Verona Pharma known for?

Verona Pharma is a biopharmaceutical company dedicated to developing innovative therapies for chronic respiratory diseases.

What are the upcoming conferences Verona Pharma will attend?

Verona Pharma will attend the TD Cowen Health Care Conference and the Leerink Partners 2025 Global Healthcare Conference in March 2025.

How can I watch Verona Pharma's conference presentations?

Webcasts of the conference presentations will be available on the Events and Presentations link on the Investors page of Verona Pharma's website.

What is Ohtuvayre™ (ensifentrine)?

Ohtuvayre™ (ensifentrine) is an inhaled therapy for maintaining COPD treatment, combining dual actions of bronchodilation and anti-inflammation.

How can I contact Verona Pharma for investor inquiries?

You can contact Victoria Stewart, the Senior Director of Investor Relations, at IR@veronapharma.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NYSE Reflects on 9/11: Honoring Lives and Legacy

Updated Category News Views 7

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Continue Reading
Sustainability Investments: $17 Trillion Wager Faces Divergence

Updated Category News Views 4

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 8

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 4

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 11

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 5

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Lick the Plate Hits 2,000 Shows with Clown Band

Updated Category News Views 5

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
2026 Buy-Side Index Reveals State Market Variance

Updated Category News Views 6

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...

Continue Reading
High-Grade Copper Spurs Optimism for PolarX in Alaska

Updated Category News Views 4

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Continue Reading

Top 5 Most Recently Viewed Articles

Hawaiian Holdings Achieves Remarkable Stock Milestone

Updated Category News Views 54

Hawaiian Holdings Stock Hits New High In an impressive show of resilience, Hawaiian Holdings Inc. (NASDAQ: HA) has reached a remarkable 52-week high of $17.76. This achievement marks a significant rebound for the airline, reflecting a stock price that has more than doubled in the past year with a striking 124.97% increase. This week's peak indicates growing investor...

Continue Reading
Zebra Technologies Enhances Brand Engagement with PR Agency

Updated Category News Views 208

Zebra Technologies Partners with Ruder Finn to Boost Brand Presence Zebra Technologies Corporation, a frontrunner in digitizing and automating frontline workflows, has enlisted Ruder Finn as its public relations Agency of Record for the Americas. This strategic collaboration aims to elevate Zebra’s brand visibility while highlighting its transformative impact on...

Continue Reading
Infortar Expands Portfolio with Full Ownership of Subsidiary

Updated Category News Views 163

Infortar Strengthens Its Position in Real Estate Aktsiaselts Infortar has recently made a strategic move by acquiring a full ownership stake in OÜ INF Saue. This acquisition allows Infortar to consolidate its real estate operations, further broadening its scope and reach in the market. OÜ INF Saue was previously partially owned, with Infortar purchasing the remaining...

Continue Reading
Class Action Lawsuit Filed Against AppLovin Corporation Over Fraud Claims

Updated Category News Views 169

Class Action Lawsuit Filed Against AppLovin Corporation Pomerantz LLP has announced a significant class action lawsuit against AppLovin Corporation (NASDAQ: APP), focusing on serious allegations pertaining to securities fraud. Investors are encouraged to reach out to legal representatives if they have experienced financial losses due to their investments in AppLovin....

Continue Reading
Immunic, Inc. Experiences Market Trials Amidst Stock Low

Updated Category News Views 130

Stock Performance Overview Immunic, Inc. (NASDAQ: IMUX) has encountered turbulence in a competitive market, with its stock price dropping to a 52-week low of $0.97. This decline indicates a notable decrease in value compared to previous assessments, with a year-to-date change of -18.07%. Despite this downturn, the company holds a robust liquidity position, characterized...

Continue Reading